If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Business Operations » Financial Management
Metrics, Graphics, Detailed Process Map
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Non-members: Click here to sign-up for a complimentary tour of
"Resources Required to Manage Winning Commercial Operations in U.S. Pharmaceutical Finance"
In today’s marketplace, pharmaceutical and biotechnology companies that operate in the U.S. market are experiencing intense pricing, political, regulatory and market pressures that create stress on the industry’s fundamental business model. Consequently, pharmaceutical and biotechnology companies – both large and small – are pressed to evaluate what’s the optimal level of human and capital investment in the commercial enterprise to ensure health and competitiveness. Due to increasing price and margin pressures, few companies can afford not to pay attention to how many people it staffs to critical functions.
This benchmarking study was designed to help provide pharmaceutical and biotech managers with insights about the levels of staff investment being channeled into their Finance functions across the industry. The benchmarks will permit senior executives and managers to assess their staffing and investment levels compared to the the industry as a whole.
The key function/activity areas examined include:
Pharmaceutical; Medical Device; Biotech; Chemical
Roche; Biogen Idec; GlaxoSmithKline; Sigma-Tau; Berlex; Stiefel Laboratories; Solvay; Boehringer Ingelheim